KALA BIO, Inc.
KALA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.19
KIRA · Stoqly’s AI analyst, in plain words
- KALA BIO, Inc. had $0.0M of revenue in fiscal 2025.
- KALA BIO, Inc. lost $27.0M in fiscal 2025.
Market cap
$0.0M
P/E
0.0x
Revenue
$0.0M
Net income
−$27.0M
Free cash flow
—
Operating margin
—
KALA BIO, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$27.0M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What KALA BIO, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- KALA BIO, Inc.
- CIK
- 0001479419
KALA BIO, Inc. · KALA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.2M | $3.9M | $0.0M | $0.0M | $0.0M |
| Revenue growth | 76.7% | −65.4% | −100.0% | — | — |
| Operating margin | −1,158.8% | −2,099.3% | — | — | — |
| Net income | −$143M | −$44.8M | −$42.2M | −$38.5M | −$27.0M |
| Net margin | −1,268.7% | −1,151.6% | — | — | — |
| Diluted EPS | −$108.32 | −$29.48 | −$17.35 | −$10.15 | −$3.31 |
| Cash | |||||
| Cash from operations | −$108M | −$78.9M | −$27.9M | −$29.4M | −$32.0M |
| Share count change | −97.5% | 15.5% | 59.9% | 56.1% | 114.7% |
| Debt and strength | |||||
| Cash and short-term investments | $92.1M | $70.5M | $50.9M | $51.2M | $7.6M |
| Debt incl. finance leases | $80.0M | $43.3M | $34.0M | $29.3M | — |
| Shareholders' equity | $16.8M | $19.0M | $7.5M | $12.3M | $7.0M |
| Current ratio | 3.3x | 3.3x | 6.3x | 3.1x | 3.8x |
| Interest coverage | −15.5x | −11.2x | −6.8x | −7.1x | −12.0x |
| Returns and quality | |||||
| Return on capital | −2,204.2% | — | — | — | — |
| Return on equity | −244.2% | −250.6% | −318.7% | −388.3% | −279.2% |
| Return on tangible equity | −848.6% | −236.2% | −562.4% | −312.3% | −385.6% |
| Piotroski F-score | 3 | 3 | 2 | 3 | 1 |
| Altman Z'' | −14.7 | −23.5 | −36.1 | −39.7 | −258.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KALA BIO, Inc. · KALA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.19 a share, the company is worth $0.0M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001479419). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.